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Background: Cluster randomized trials are increasingly being used in healthcare evaluation to show the
effectiveness of a specific intervention. Care pathways (CPs) are becoming a popular tool to improve the quality of
health-care services provided to heart failure patients. In order to perform a well-designed cluster randomized trial
to demonstrate the effectiveness of Usual care (UC) and CP in heart failure treatment, the intraclass correlation
coefficient (ICC) should be available before conducting a trial to estimate the required sample size. This study
reports ICCs for both demographical and outcome variables from cluster randomized trials of heart failure patients
in UC and care pathways.
Methods: To calculate the degree of within-cluster dependence, the ICC and associated 95% confidence interval
were calculated by a method based on analysis of variance. All analyses were performed in R software version
2.15.1.
Results: ICCs for baseline characteristics ranged from 0.025 to 0.058. The median value and interquartile range was
0.043 [0.026-0.052] for ICCs of baseline characteristics. Among baseline characteristics, the highest ICCs were found
for admission by referral or admission from home (ICC = 0.058) and the disease severity at admission (ICC = 0.046).
Corresponding ICCs for appropriateness of the stay, length of stay and hospitalization cost were 0.069, 0.063, and
0.001 in CP group and 0.203, 0.020, 0.046 for usual care, respectively.
Conclusion: Reported values of ICCs from present care pathway trial and UC results for some common outcomes
will be helpful for estimating sample size in future clustered randomized heart failure trials, in particular for the
evaluation of care pathways.
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Cluster randomized trials (CRTs) are increasingly used
to evaluate the effectiveness of health-care interventions
[1]. In CRTs, patients are nested within clusters such as
hospitals, communities or practices, and interventions
are applied at cluster levels but outcomes are measured
at the individual level. It is expected that individuals in
the same cluster, e.g. geographical area, hospital, would
have more similarities compared to individuals in different
clusters [2]. This similarity may occur because patients in* Correspondence: sevalkul@gantep.edu.tr
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reproduction in any medium, provided the orthe same clusters interact with each other and receive
care from the same practitioners. Intraclass correlation
coefficient (ICC) is used to determine the degree of within-
cluster dependence and it plays an important role in
estimating sample size for cluster randomized trials [3].
In cluster randomised trials, traditional sample size es-
timation techniques for RCTs lead to underestimation of
the required sample size [3,4] and because individuals in
the same organization or clusters are not independent,
the sample size must be inflated [4]. The degree of the
increase in sample size is a function of both ICC and
cluster sizes where generally a greater ICC requires enroll-
ment of a greater number of patients in the trial [3].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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worldwide associated with a high prevalence, mortality
rate and hospital costs. It is estimated that about 5.7 mil-
lion people are afflicted by CHF in the United States [5]
and in Europe approximately 5% of all acute medical ad-
missions are HF-related [6]. The estimated direct and in-
direct costs of HF management in the United States
totaled $39.2 billion in 2010 [7]. It was reported that the
cost of HF care is two times higher than that of breast
cancer, and three times higher compared to costs of
colorectal and lymphoma cancer care in the USA [8].
Care Pathway (CP) is a complex intervention for the
mutual decision making and organisation of care processes
for a well-defined group of patients during a well-defined
period [9]. CPs are also known as “integrated care path-
ways”, “critical pathways”, “care plans”, “clinical pathways”,
“care maps” and “care protocols” [10]. CPs have become a
popular tool to improve quality of health-care services
provided to CHF patients by reducing the risks of mortal-
ity [11-13] and readmission [14,15] leading to shorter
length of stay [13,14] and lower costs [13,14]. CPs are
utilized to evaluate one specific care plan. Each hospital
included in CPs uses the same protocol in practice.
Many articles are available in Medline and medical data-
bases describing the concept and success of CPs [9-11].
According to the European Care Pathway Association
(an international non-profit association), the defining
characteristics of CPs include: (i) an explicit statement
of the goals and key elements of care, based on evidence,
best practice, and patients’ expectations and their charac-
teristics; (ii) the facilitation of the communication among
the team members and with patients and families; (iii) the
coordination of the care process by coordinating the roles
and sequencing the activities of the multidisciplinary care
team, patients and their relatives; (iv) the documentation,
monitoring, and evaluation of variances and outcomes;
and (v) the identification of the appropriate resources. The
aim of a care pathway is to enhance the quality of care,
across the continuum, by improving risk-adjusted patient
outcomes, promoting patient safety, increasing patient
satisfaction, and optimizing the use of resources [16].
In order to conduct a well-designed CRT with the aim
to show the effectiveness of CPs for a CHF treatment,
ideally, the ICC should be known beforehand to estimate
required sample size and statistical power to decrease
the chances of type II error [17]. A range of ICCs has
been reported previously [17-22]; however, it is often dif-
ficult to obtain an appropriate ICC value for a specific
study from the published ICC estimates. The present
study reports ICCs for both demographical and outcome
variables from cluster randomized trials of heart failure
patients in the setting of usual care (UC) and care path-
ways (CP). Reported values of ICCs obtained from the
UC and care pathway trials for some common outcomeswould be useful to estimate sample size in future CP
trials.
Methods
Experimental design
The intraclass correlation coefficients and confidence in-
tervals for outcome variables of interest were calculated
from a multi-center CRT which assessed in-hospital treat-
ment of heart failure. In the present study, 14 community
hospitals were randomized either to care pathway or usual
care. Data were collected from March 2003 to October
2004 prospectively by trained physicians and nurses.
All patients with a primary diagnosis of HF who re-
ceived in-hospital treatment and patients with acute myo-
cardial infarction or unstable angina were enrolled. One
physician or nurse with at least 2 years of experience in
CP was assigned to each hospital in the experimental
group. The final sample consisted of 429 patients (CP, n =
214 and UC, n = 215). The trial was successful in reducing
in-hospital mortality and unscheduled readmissions in the
care pathway group.
More details about the study protocol and intervention
have been previously described elsewhere [13,23].
Ethics
The project was exempt from ethical clearance according
to the Italian Ministry of Health law number (ex art. 12bis
D.lgs 229/99). Moreover the aim of the study is to improve
quality of care through clinical pathways and thus should
not imply any risk for the patients affected by the study. It
is difficult to imagine that our intervention based on better
evidences and appropriate use of technologies and drugs
could worsen the quality of care when compared to usual
care. So according to other experiences dealing with clin-
ical pathways or implementation of evidence based guide-
lines in practice we think that a Committee of Research
Ethic would not consider it necessary to submit the proto-
col for approval.
Statistical method
To calculate the degree of within-cluster dependence, the
ICCs for continuous variables and ordinal variables were
calculated by the formula which was derived by Donner
and Klar based on an analysis of variance [24];
ICC ¼ S
2
b
S2b þ S2w
 
where:
s2b is the variance between clusters, and s
2
w is the variance
within clusters.
The confidence interval estimates for continuous var-
iables and ordinal variables were calculated using the
approximate formulas for the standard error of the ICC
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binomial data were calculated using the logistic binomial-
Gaussian model [26] and 500 replicates boostrap confi-
dence interval estimations were presented to increase the
precision of the estimates [27].
Design effect is the ratio between the number of subjects
in the cluster study and the number of subjects in an
equally reliable, randomly sampled unclustered study [28].
It is defined as the ratio of two variances: the variance of
the estimator when the effect of clustering is taken into
account over the variance of the estimator under the hy-
pothesis of a simple random sample [3]. The design ef-
fect is estimated by using the following formula: Design
effect = 1+ [m-1]*ICC. m is the average number of the
individuals in each cluster [3]. The design effect varies
for each outcome. Negative ICCs were truncated at zero
because it has been suggested that negative ICCs should
not be used for sample size calculation in CRTs [2].
All analyses were performed using R software version
x2.15.1. The ICCs for continuous and ordinal variables
were calculated using multilevel package and ICC esti-
mates for binary variables and boostrap confidence inter-
vals were calculated using aod package in R.
Results
ICCs and 95% confidence intervals (CIs) were calcu-
lated for 429 heart failure patients (CP, n = 214 and UC,
n = 215). Data were collected from 14 hospitals. Cluster
size ranged between 30 to 32 and average cluster sizeTable 1 Baseline characteristics of the sample in clusters
No n Age* (years) Male†
6
CP 2 30 80.50 (8.32) 56.7 3
CP 3 31 79.39 (9.32) 48.4 1
CP 4 30 82.00 (7.49) 46.7 6
CP 5 31 82.13 (8.54) 41.9 3
CP 6 31 83.39 (7.32) 48.4 1
CP 7 31 82.29 (7.00) 51.6 3
UC 8 30 81.43 (8.61) 50.0 6
UC 9 30 78.77 (10.08) 53.3 3
UC10 32 78.94 (9.610) 46.9 0
UC11 31 76.23 (8.09) 51.6 6
UC12 30 80.53 (7.32) 53.3 6
UC13 30 82.60 (7.74) 40.0 1
UC 14 32 79.22 (6.48) 62.5 1
Total 429 80.66±8.41 49.4 7
CP: Care Pathways; UC: Usual Care; No: number of cluster; n: cluster size, COPD: Chr
HT: hypertension; CM: comorbidity.
*Continuous variables (mean (SD)).
†Ordinal or Binary variable (%).was 30.64. For ICC estimates of baseline characteristics,
all centers was used because the intervention has not
yet occurred. Baseline characteristics and outcome vari-
ables of the study are presented in Table 1 and Table 2
respectively. Mean age of the study participants was
81.66 ±8.41 years (range: 50–99) and 49.4% of them
were males. The most common health problems among
the study patients were hypertension (73.7%] and co-
morbidities such as COPD, diabetes and smoking (32.9%].
48.5% of the patients admitted following referral by a
general practitioner.
The mean length of hospital stay (LOS) for UC and
CP patients was 11.42 ± 6.69 and 10.35 ± 5.17 days, with
a mean cost of hospitalization of €2211.66 ± €574.76 and
€2125,66 ± €530.93, respectively. In-hospital mortality rates
were 15.3% in UC and 5.6% in the CP groups and the
mean rates of unscheduled readmission for UC and CP
were 14.0% and 7.9% respectively.
Tables 3 and 4 provide estimates of intraclass correlation
coefficients, 95% confidence intervals and design effects
for baseline characteristics for each cluster and outcomes
of the clustered sample selected from 14 hospitals (7 CP,
7 UC).
ICCs for baseline characteristics ranged from 0.025 to
0.058. The median value and interquartile range for ICCs
of baseline characteristics was 0.043 [0.026-0.052]. Among
baseline characteristics, the highest ICCs were found for
referrals by a general practitioner or admission from home
(ICC = 0.058) and hypertension (ICC = 0.043) (Table 3).NYHA† class at admission
HT† CM†
II III IV
.7 40.0 53.3
.3 56.7 40.0 66.7 20.0
2.9 58.1 29.0 71.0 29.0
.7 63.3 30.0 73.3 30.0
.2 71.0 25.8 64.5 29.0
6.1 54.8 29.0 71.0 19.4
.2 41.9 54.8 80.6 29.0
.7 46.7 46.7 83.3 50.0
.3 50.0 46.7 83.3 43.3
.0 56.3 43.8 71.9 43.8
.5 51.6 41.9 74.2 38.7
.7 40.0 53.3 86.7 43.3
0.0 50.0 40.0 86.7 40.0
5.6 75.0 9.4 40.6 9.4
.2 54.1 38.7 73.7 32.9
onic obstructive pulmonary disease, NYHA: New York Heart Association;
Table 2 Outcome variables of the present study in clusters
No n LOS* (days) Cost (€)*
NYHA† class at discharge
Mortality† AOS† UR†
II III IV
CP 1 30 10.97 (5.44) 2227.30 (591.83) 42.9 53.6 3.6 6.7 96.7 6.7
CP 2 30 13.13 (5.94) 2171.77 (470.22) 39.3 57.1 3.6 3.3 73.3 0.0
CP 3 31 9.13 (4.33) 2077.87 (550.71) 48.3 51.7 0.0 6.5 77.4 9.7
CP 4 30 8.27 (4.82) 2113.47 (550.89) 46.4 50.0 3.6 6.7 73.3 13.3
CP 5 31 10.35 (4.72) 2089.52 (482.24) 31.0 65.5 3.4 6.5 58.1 6.5
CP 6 31 9.48 (4.86) 1969.10 (571.62) 50.0 46.7 3.3 3.2 64.5 16.1
CP 7 31 11.13 (4.98) 2234.29 (489.18) 31.0 65.5 3.4 6.5 90.3 3.2
Total CP 214 10.35 (5.17) 2125.56 (530.93) 41.3 55.7 3.0 5.6 76.2 7.9
UC 8 30 12.33 (7.63) 2207.53 (591.92) 24.0 64.0 12.0 16.7 83.3 13.3
UC 9 30 10.93 (6.11) 2322.50 (488.25) 45.5 40.9 13.6 20.0 76.7 10.0
UC10 32 10.13 (5.83) 2290.13 (525.57) 23.1 61.5 15.4 15.6 78.1 12.5
UC11 31 11.26 (6.00) 2243.74 (480.45) 11.1 74.1 14.8 12.9 77.4 16.1
UC12 30 9.43 (6.13) 2380.37 (719.91) 8.0 84.0 8.0 16.7 90.0 20.0
UC13 30 11.70 (6.82) 2150.43 (613.75) 25.9 66.7 7.4 10.0 76.7 23.3
UC 14 32 14.06 (7.65) 1898.31 (490.99) 77.8 22.2 0.0 15.6 25.0 3.1
Total UC 215 11.42 (6.69) 2211.21 (574.76) 30.7 59.2 10.1 15.3 72.1 14.0
No: number of cluster; n: cluster size; LOS: length of hospital stay; NYHA: New York Heart Association, AOS: Appropriateness of the stay; UR: Unscheduled readmission.
*Continuous variables (mean (SD)).
†Ordinal or Binary variable (%).
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dividual randomized trial as would be obtained by a CRT,
the number of subjects enrolled in the study should be
multiplied by 2.68 and 2.25, respectively for a mean cluster
size of 30. As shown in Table 4, ICC estimates of outcome
variables in the CP group ranged from 0.001 for in-
hospital mortality and disease severity at discharge to
0.069 for appropriateness of the stay (AOS) and median
value and interquartile range for outcome measures ICCs
was 0.006 [0.001-0.065]. The estimates for appropriateness
of the stay, length of stay were 0.069 [0.003-0.155] and,
0.063 [0.007-0.311], respectively.
ICC estimates of outcome variables in the UC group
ranged from 0.001 for in-hospital mortality to 0.203 for
appropriateness of the stay (AOS) and median value and
interquartile range for ICCs of outcome variables wasTable 3 Intraclass correlation coefficients for baseline
characteristics of the sample selected from 14 hospitals
Variable ICC 95% CI
Age* 0.025 0.000-0.102
Disease Severity at Admission (NHYA)† 0.046 0.007-0.145
Admitted from Home or Referred by GP† 0.058 0.000-0.128
Co-morbidities† 0.027 0.000-0.066
Hypertension† 0.043 0.000-0.101
DE: Design effect, GP: General practitioner, COPD: Chronic obstructive
pulmonary disease, NYHA: New York Heart Association; CI: confidence interval.
*Ordinal or Continuous variables.
†Binary variables.0.033 [0.003-0.187]. The estimates for appropriateness of
the stay and disease severity at discharge were 0.203
[0.059-0.436], and 0.182 [0.062-0.554], respectively.Discussion
In the present study, ICCs and their associated 95% confi-
dence intervals were calculated for clinical and patient-
related outcome variables based on the results of an Italian
multi-center cluster randomized trial of heart failure.
In recent years, the need to have published ICCs from
different CRTs was put forward to help planning future
studies [29-31]. Also several studies reported estimates
of ICCs for various outcomes and for different treatment
modalities [18,29,32]. However, this is the first study to
present ICCs for a cluster randomized trial of care
pathway. In addition, most of the studies have reported
ICCs obtained in the setting of primary or residential
care [19,22,29,33,34]. This study provides ICCs for a
specific in-hospital treatment. Moreover, while some
studies reported ICCs for many cardiovascular inter-
ventions [18,22,25], none of them reported ICCs for
outcomes such as in-hospital mortality or length of
hospital stay to determine effectiveness and efficiency
of heart failure treatment. Although a well-designed
CRT was conducted with the aim to show the effect of
pharmacological treatment on heart failure [35,36],
ICC estimates are still lacking. To our best knowledge,
this is also the first study to present ICCs for multiple
Table 4 Intraclass correlation coefficients for the outcomes variables of study
Usual care Care pathways
Outcome variables ICC 95% CI ICC 95% CI
LOS (days)* 0.020 0.000-0.184 0.063 0.007-0.311
Cost (€)* 0.046 0.001-0.265 0.001 0.000-0.107
In-hospital mortality† 0.001 0.000-0.003 0.001 0.000-0.003
Disease Severity at Discharge (NYHA)† 0.182 0.062-0.554 0.000 0.000-0.076
AOS† 0.203 0.059-0.436 0.069 0.003-0.155
Unscheduled readmission† 0.004 0.000-0.036 0.010 0.000-0.046
DE: Design effect, AOS: Appropriateness of the stay, NYHA: New York Heart Association, CI: confidence interval.
*Ordinal or Continuous variable.
†Binary variables.
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and efficiency of in-hospital treatment of heart failure.
We hope that our estimates will be helpful in designing
a clinical experiment not only for CPs but also for any
clustered RT in heart failure patients. However, we believe
that there is one critical point that should be considered
by any researcher who would intend to use these esti-
mates. We often observed less variation in different clus-
ters in the CPs compared to the UC in many cases
because all of the hospitals in the care pathway group used
the same protocol and they were informed and trained in
the same way; thus, ICC estimates tended to be lower,
which implies the presence of larger within- cluster
variance. The variance within clusters may be reduced
by adjusting the subject-specific covariates in order to
improve the accuracy of the ICC estimation.
It has been reported that ICCs were usually between
0.01 and 0.02 in human studies [34] and the Minnesota
Heart Health Program Trial, the largest community trial
for prevention of coronary heart disease to date, found
ICCs which generally ranged between 0.002-0.012. In
our study, the range of ICCs was wider (Tables 3 and 4).
We conducted a literature search to identify ICC esti-
mates of variables similar to those in our study to compare
our results. Previously published ICC estimates were avail-
able only for hypertension. We observed a moderate de-
pendency for hypertension and previous estimates were
also rather low for hypertension.
In primary care, physician practices would be expected
to be more independent and previous studies showed
that the ICC estimates derived from secondary care were
greater than those from primary care [37]. In contrast to
other studies, we found greater ICCs for outcome vari-
ables such as LOS, AOS and cost, whereas the ICCs for
baseline characteristics tended to be lower. High ICCs
estimated for LOS, AOS and cost indicated that patients
staying in the same hospital shared many common char-
acteristics other than patients in other hospitals. In other
words, for these outcomes, HF management was more
likely to be influenced by the practice itself or to berelated with physician’s practice style. A care pathway is
performed to encourage physicians practice more con-
sistently. If the intervention is successful, it is expected
that ICC based on post-intervention data would be
smaller than an ICC based on pre-intervention data [38].
Based on our data, ICC value for the disease severity at ad-
mission [ICC = 0.046] was higher than that of disease sever-
ity at discharge in the care pathway group [ICC = 0.000].
This result confirms the success of the intervention and
also consistency of the ICC estimates.
Estimation of the effect size or minimally important
effect of intervention is another important consideration
for sample size calculation. It is usually obtained from
the published literature. Since a CRT design was used in
the current study, our results may be helpful for estimating
the effect size in future randomized trials of in-hospital
treatment of heart failure.
Adjustment for the data variations in cluster was ad-
vised in many publications with regard to baseline covar-
iates and factors such as age and gender based on the
idea that different distributions across clusters could
have an effect on ICC estimations. Several methods for
adjustment have been discussed [39,40]. However, we
did not make any adjustment because our clusters were
very similar to each other with respect to baseline char-
acteristics (Table 1). The results of this study were de-
rived from patients between 50 and 99 years of age and
may be extrapolated to other patients older than 50 years
of age.
Many estimators have been proposed for binary out-
comes [41] and point estimation by ANOVA is most
commonly used for calculating ICC for continuous data
[42]. Also there are several published studies which re-
ported ICCs and each of them reported their ICC values
in their own way. To ensure that all of the necessary
information was presented in our report, we provided
compressive information for reporting ICCs by using a
framework reported by Campbell et al. in 2004 [37].
Since sample size estimation is a key element of a clin-
ical trial, many new techniques have been introduced for
Kul et al. BMC Health Services Research 2014, 14:84 Page 6 of 7
http://www.biomedcentral.com/1472-6963/14/84cluster randomized clinical trials in the recent publications.
Campbell et al. was performed a study to generate empir-
ical estimates of ICCs and to explore factors which may
affect their magnitude [38]. Furthermore, Turner et al. pro-
vided Bayesian methods of analysis for cluster randomized
trials with binary outcome data [43]. Campbell et al.
presented the development of a sample size calculator
for cluster randomized trials and described strategies
for increasing the sample size [44]. This calculator allows
the investigator to trade-off the options for achieving the
appropriate sample size. Most cluster randomized trials
have unequal cluster sizes. Moreover, Eldridge et al. (2006)
[45] showed how coefficient of variation of a cluster size
can be used to deduce the possible effect of unequal clus-
ter sizes for various types of analyses and both continuous
and binary outcomes. Their simple formula provides a
good estimate of sample size requirements for trials ana-
lysed using cluster-level analyses weighted by cluster size
and a conservative estimate for other types of analyses.
Furthermore, Sample size formulae for CRCTs with a
fixed number of clusters for both continues and binary
outcomes were systematically outlined by Hemming et al.
[46]. In addition that Rotondi and Donner (2012) provided
an evidence-based approach [47] and authored an R pack-
age to facilitate sample size estimation in this design (CRT
Size). In this approach, sample size for clustered random-
ized trials was estimated taking into account the role of
the planned trial on a future meta-analysis [48].
In the cluster randomized trials, the design effects are
calculated using the cluster sizes from the existing data
set and anyone planning a trial will need to calculate
their sample size on their own. Thus, we did not report
the design effects because it would not be useful for
researchers planning their own trials.
There are some potential limitations of this study. The
first limitation is the absence of any published ICC values
for any care pathway or in-hospital treatment of heart fail-
ure. We have only been able to compare our results with
ICCs estimated for different kinds of treatments. Second
limitation of this study was that the data were collected
between 2003 and 2004, to the best of our knowledge; this
is the latest multicenter cluster randomized trial to show
the effectiveness of CPs on the heart failure treatment.
Also, no ICC values have been reported in literature for
hospital treatment of heart failure up to date. But there is
no evidence about the timeless of the material. So the
readers should be aware of that changes in the treatment
methodology can affect the ICC estimations and one
should consider limitations of this study while using the
ICC estimation of the present study.
Conclusions
Although there are many previously published reports on
ICC estimates, studies vary with respect to setting andoutcome variables of interest. Also, it is often difficult to
obtain a reliable ICC estimate applicable for a proposed
study [17]. Therefore, specific ICC estimates are needed to
design a CRT for heart failure treatment. In the present
study, ICCs for multiple outcomes were reported with the
aim to help facilitate the design process of future cluster
randomized trials, particularly for therapeutic interven-
tions for hospitalized heart failure patients.
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